Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALA Calithera Biosciences	$0.00	$0.00	$0.00 ▼ $0.05	N/A	-2.82	12,005 shs	194 shs
CLSD Clearside Biomedical	$0.41 -31.9%	$0.82	$0.32 ▼ $1.65	$31.86M	2.05	389,652 shs	3.61 million shs
MIST Milestone Pharmaceuticals	$1.58 -4.2%	$1.67	$0.63 ▼ $2.75	$84.47M	0.96	1.13 million shs	1.74 million shs
SCYX SCYNEXIS	$0.73 -2.0%	$0.80	$0.66 ▼ $2.28	$28.29M	1.57	166,607 shs	147,473 shs
XCUR Exicure	$7.93 +2.9%	$8.59	$1.44 ▼ $36.00	$50.12M	3.57	580,398 shs	95,083 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALA Calithera Biosciences	0.00%	0.00%	0.00%	-98.00%	-99.20%
CLSD Clearside Biomedical	-28.01%	-31.26%	-23.82%	-30.02%	-50.26%
MIST Milestone Pharmaceuticals	-1.20%	-35.55%	-4.62%	+85.62%	+6.45%
SCYX SCYNEXIS	-2.63%	+5.71%	-1.33%	-18.17%	-65.90%
XCUR Exicure	+17.89%	+5.91%	-7.33%	-8.65%	+2,395.15%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CALA Calithera Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CLSD Clearside Biomedical	2.3687 of 5 stars	4.1	3.0	0.0	0.0	2.4	0.0	0.0
MIST Milestone Pharmaceuticals	2.7814 of 5 stars	3.2	4.0	0.0	0.0	2.9	2.5	0.0
SCYX SCYNEXIS	0.9204 of 5 stars	0.0	3.0	0.0	0.0	3.3	0.8	0.6
XCUR Exicure	1.518 of 5 stars	0.0	3.0	0.0	4.7	3.3	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CALA Calithera Biosciences	0.00	N/A	N/A	N/A
CLSD Clearside Biomedical	2.20	Hold	$4.20	924.39% Upside
MIST Milestone Pharmaceuticals	2.40	Hold	$7.00	343.04% Upside
SCYX SCYNEXIS	0.00	N/A	N/A	N/A
XCUR Exicure	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest MIST, XCUR, CLSD, CALA, and SCYX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/18/2025	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$5.00
7/18/2025	CLSD Clearside Biomedical	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/18/2025	CLSD Clearside Biomedical	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$2.00
7/17/2025	CLSD Clearside Biomedical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold	$3.00
6/5/2025	MIST Milestone Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$5.00
5/23/2025	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $5.00
5/16/2025	CLSD Clearside Biomedical	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00 ➝ $5.00
5/15/2025	CLSD Clearside Biomedical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CALA Calithera Biosciences	N/A	N/A	N/A	N/A	N/A	N/A
CLSD Clearside Biomedical	$1.66M	19.19	N/A	N/A	($0.51) per share	-0.80
MIST Milestone Pharmaceuticals	$1M	84.47	N/A	N/A	$0.25 per share	6.32
SCYX SCYNEXIS	$2.63M	10.76	N/A	N/A	$1.45 per share	0.50
XCUR Exicure	$500K	100.24	N/A	N/A	$1.12 per share	7.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CALA Calithera Biosciences	-$39.65M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CLSD Clearside Biomedical	-$34.35M	-$0.41	N/A	N/A	N/A	-818.57%	N/A	-114.23%	8/11/2025 (Estimated)
MIST Milestone Pharmaceuticals	-$41.52M	-$0.78	N/A	N/A	N/A	N/A	-329.85%	-67.20%	8/6/2025 (Estimated)
SCYX SCYNEXIS	-$21.29M	-$0.56	N/A	14.50	N/A	-1,030.04%	-53.47%	-32.86%	8/6/2025 (Estimated)
XCUR Exicure	-$9.70M	-$3.82	N/A	∞	N/A	N/A	-219.60%	-82.03%	8/12/2025 (Estimated)

Latest MIST, XCUR, CLSD, CALA, and SCYX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	MIST Milestone Pharmaceuticals	-$0.18	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	SCYX SCYNEXIS	-$0.23	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	CLSD Clearside Biomedical	-$0.12	N/A	N/A	N/A	$0.50 million	N/A
6/27/2025	Q1 2025	XCUR Exicure	N/A	-$0.45	N/A	$0.49	N/A	N/A
5/15/2025	Q1 2025	SCYX SCYNEXIS	-$0.23	-$0.17	+$0.06	-$0.11	$0.14 million	$0.26 million
5/14/2025	Q1 2025	CLSD Clearside Biomedical	-$0.12	-$0.11	+$0.01	-$0.11	$0.20 million	$2.33 million
5/14/2025	Q1 2025	MIST Milestone Pharmaceuticals	-$0.19	-$0.31	-$0.12	-$0.31	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CALA Calithera Biosciences	N/A	N/A	N/A	N/A	N/A
CLSD Clearside Biomedical	N/A	N/A	N/A	N/A	N/A
MIST Milestone Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SCYX SCYNEXIS	N/A	N/A	N/A	N/A	N/A
XCUR Exicure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CALA Calithera Biosciences	N/A	N/A	N/A
CLSD Clearside Biomedical	N/A	3.19	3.19
MIST Milestone Pharmaceuticals	4.06	4.67	4.67
SCYX SCYNEXIS	N/A	5.83	5.83
XCUR Exicure	N/A	2.91	2.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CALA Calithera Biosciences	N/A
CLSD Clearside Biomedical	18.75%
MIST Milestone Pharmaceuticals	86.18%
SCYX SCYNEXIS	54.37%
XCUR Exicure	42.82%

Insider Ownership

Company	Insider Ownership
CALA Calithera Biosciences	6.60%
CLSD Clearside Biomedical	6.20%
MIST Milestone Pharmaceuticals	19.50%
SCYX SCYNEXIS	4.86%
XCUR Exicure	3.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CALA Calithera Biosciences	60	4.87 million	4.55 million	Not Optionable
CLSD Clearside Biomedical	30	77.71 million	72.89 million	Optionable
MIST Milestone Pharmaceuticals	30	53.46 million	43.04 million	Optionable
SCYX SCYNEXIS	60	39.02 million	37.12 million	Optionable
XCUR Exicure	50	6.32 million	6.07 million	Not Optionable

MIST, XCUR, CLSD, CALA, and SCYX Headlines

Recent News About These Companies

Is Exicure Stock (XCUR) Experiencing a Dead Cat Bounce?

June 30, 2025 | msn.com

Exicure Shares Up After Swing to Profit in 1Q

June 27, 2025 | marketwatch.com

Exicure, Inc. Reports First Quarter 2025 Financial Results

June 27, 2025 | businesswire.com

Exicure (NASDAQ:XCUR) Stock Price Down 5.8% - Here's Why

June 18, 2025 | marketbeat.com

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

May 28, 2025 | businesswire.com

Why Exicure Inc. (XCUR) Soared on Monday

April 22, 2025 | msn.com

Exicure’s subsidiary, GPCR Therapeutics doses 19th patient in its phase 2 study of GPC-100 in multiple myeloma

April 16, 2025 | pharmabiz.comP

Exicure to initiate new clinical trial in acute myeloid leukaemia with GPC-100

April 15, 2025 | pharmabiz.comP

Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

April 14, 2025 | businesswire.com

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in ...

April 11, 2025 | gurufocus.com

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

April 11, 2025 | investing.com

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

April 11, 2025 | businesswire.com

Wednesday’s Insider Moves: Top Buys and Sells in US Stocks

March 27, 2025 | investing.com

Exicure, Inc. Reports Full Year 2024 Financial Results

March 18, 2025 | gurufocus.com

Exicure secures Australian patent for cancer treatment

March 15, 2025 | investing.com

Exicure announces issuance of new patent in Australia

March 15, 2025 | markets.businessinsider.com

Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia

March 13, 2025 | gurufocus.com

Kuehn Law Encourages Investors of Exicure, Inc. to Contact Law Firm

January 27, 2025 | markets.businessinsider.com

Exicure announces purchase agreement with GPCR Therapeutics

January 24, 2025 | markets.businessinsider.com

CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

January 22, 2025 | businesswire.com

Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

January 22, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode

MIST, XCUR, CLSD, CALA, and SCYX Company Descriptions

Calithera Biosciences NASDAQ:CALA

$0.0001 0.00 (0.00%)

As of 09:30 AM Eastern

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Clearside Biomedical NASDAQ:CLSD

$0.41 -0.19 (-31.87%)

Closing price 04:00 PM Eastern

Extended Trading

$0.42 +0.01 (+1.95%)

As of 07:58 PM Eastern

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Milestone Pharmaceuticals NASDAQ:MIST

$1.58 -0.07 (-4.24%)

Closing price 04:00 PM Eastern

Extended Trading

$1.61 +0.03 (+1.90%)

As of 07:59 PM Eastern

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

SCYNEXIS NASDAQ:SCYX

$0.72 -0.02 (-2.03%)

Closing price 04:00 PM Eastern

Extended Trading

$0.73 +0.01 (+1.10%)

As of 05:43 PM Eastern

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Exicure NASDAQ:XCUR

$7.93 +0.22 (+2.85%)

Closing price 04:00 PM Eastern

Extended Trading

$7.86 -0.07 (-0.95%)

As of 07:42 PM Eastern

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time